ArticleChest2025
Bronchiectasis in Patients With Inflammatory Bowel Diseases: Prevalence, Predictors, and Clinical Characteristics.
Article in Chest, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Autoantibody Positivity in Bronchiectasis Without Interstitial Lung Diseases: Risk Factors and Impact on Clinical Features.Journal of clinical medicine · 2026Article
- Respiratory Burden in Hematology-Related Bronchiectasis: Clinical Characteristics and Treatable Traits.Respiration; international review of thoracic diseases · 2025Article
- Screening and impact of comorbidities in bronchiectasis: a forward-looking perspective.Therapeutic advances in respiratory diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInflammatory bowel diseases (IBDs) are known to be associated with bronchiectasis (BE). However, data on patients with inflammatory bowel disease-related bronchiectasis (IBD-BE) are limited. RESEARCH QUESTION: What are the prevalence, risk factors, and clinical characteristics of IBD-BE? STUDY DESIGN AND
methodsThis was a single-center retrospective study including patients who visited an IBD unit at a tertiary center between 2022 and 2023. Data on prior chest CT scans were extracted. Radiologists masked to clinical data analyzed all chest CT scans for BE. The overall prevalence of IBD-BE was estimated using multiple imputation analysis. Risk factors were analyzed in the whole cohort and after matching.
resultsA total of 1,637 patients with IBD were included, and 254 had prior chest CT scans. Of these, 30 (1.8% of the cohort) had BE. The estimated overall prevalence of IBD-BE was 5.17% (95% CI, 3.60%-8.22%). Chest cuts of available abdominal CT scans (n = 1,048) were also analyzed identifying 19 additional cases of IBD-BE, resulting in a minimal prevalence of 3%. Ulcerative colitis, prior IBD-related surgery, and extraintestinal manifestations were risk factors for IBD-BE. Of patients with chest CT scans, 63% had evidence of BE on their prior abdominal CT scans, and 70% had relevant respiratory symptoms. Despite this, most did not see a pulmonologist nor receive BE-related therapy. Clinical characteristics and outcomes were similar to patients with non-IBD-related BE.
interpretationThis study shows a relatively high prevalence of IBD-BE. The low rates of BE-directed therapy and pulmonology referral indicate the need for a higher degree of suspicion and timely referral.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.